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Plasma creatinine may not reflect glomerular filtration rate
(GFR) especially in the early stages of chronic kidney disease
(CKD). Plasma cystatin C (cysC), however, has the potential to
more accurately determine early GFR reduction. We sought
to improve the creatinine-based GFR estimation by including
cysC measurements. We derived a reference GFR from
standard dual plasma sampling 99mTc-DTPA clearance in a
training cohort of 376 randomly selected adult Chinese
patients with CKD. We compared reference values to
estimated GFR and applied multiple regression models to
one equation based solely on cysC, and to another
combining plasma creatinine (Pcr) and cysC measurements
of the training cohort. The results were validated by testing
an additional 191 patients. The difference, precision, and
accuracy of the two estimates were compared with the
modified Modification of Diet in Renal Disease (MDRD)
equation for Chinese patients, and another estimate
combining cysC and modified MDRD calculations. The
estimated GFR combining Pcr and cysC measurements
more accurately matched the reference GFR at all stages of
CKD than the other equations, particularly in patients with
near-normal kidney function.
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The number of patients with chronic kidney disease (CKD) is
growing worldwide;1,2 CKD has been recognized as one of the
independent risk factor of cardiovascular disease (CVD), even
in its early stages.3,4 Detection of decreased kidney function and
identification of CKD in its early stage are thus very important,
but because overestimation of true glomerular filtration rate
(GFR) will lead to insufficient treatment and underestimation
of true GFR will lead to an unnecessary intervention and waste
of medical resources,5 a simple and accurate GFR estimating
method is of great clinical importance.
The Modification of Diet in Renal Disease (MDRD)
equations provided reasonable accuracy in Whites and
African Americans in GFR estimation,6 and were recom-
mended by the Kidney Disease Outcome Quality Initiatives
clinical practice guidelines.7 Recently, Levey et al. re-
expressed MDRD equations using the standardized plasma
creatinine (Pcr) assay,8 and claimed that clinical laboratories
can report more accurate GFR estimates in patients with true
GFR of less than 90 ml min1 1.73 m2. Also, modified
MDRD equations based on Chinese CKD patients showed
significant improvement compared with the original ones.9
Both original MDRD equations and the modified MDRD
equations underestimated GFR in CKD stage 1 and 2,9,10 and
re-expressed MDRD equations, however, do not perform well
in patients with higher GFR levels.8 This is partly because the
main GFR predictor in these equations is the Pcr, and Pcr’s
relationship with GFR is different among stages of CKD,9,11
and different levels of Pcr do not necessarily reflect the true
variation of GFR.12 For example, there was no significant
elevation of Pcr levels with the decrease of GFR at the very
early stages of CKD because of tubular secretion. These
phenomena contribute to the inaccuracy of Pcr-based
equations in early stages of CKD, and may be an unavoidable
pitfall of Pcr-based GFR estimation equations.
Plasma cystatin C level (cysC) increases earlier than Pcr as
GFR decreases, and may be a valuable marker in detecting
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early renal function impairment.13,14 It fulfills a number of
criteria for endogenous marker of GFR: It is freely filtered
and catabolized in the proximal tubule, without being
secreted.15 Unlike Pcr, cysC does not depend on sex and
muscle mass, and does not change with age between 1 and 50
years.15 In several studies14,16,17 and in one meta-analysis,18
cysC has been reported to be superior to Pcr in GFR
estimation, particularly in patients with near-normal kidney
function.
Researchers have developed cysC-based GFR-estimating
equations, and have compared their performance with
original MDRD equations. White et al.19 demonstrated that
cysC-based equations are more accurate in GFR prediction in
renal transplant recipients, than abbreviated MDRD equa-
tions. Poge et al.20 found that cysC-based equations might
offer advantages compared with abbreviated MDRD equa-
tions, in cirrhotic patients. Grubb et al.21 reached the similar
conclusions in patients with various renal diseases. More
recently, Rule et al.22 claimed that estimating the geometric
mean of a cysC-based equation and a Pcr-based equation
improved GFR estimation.
In this study, an GFR equation was developed by a log
transformed regression model, which simultaneously used
Pcr and cysC as independent variables, and compared with
the modified MDRD equation for Chinese and a composite
equation constituted from the modified MDRD equation and
a solely cysC equation.
RESULTS
Patients’ characteristics
Five hundred and sixty-seven patients with CKD (average age
was 49.8716.3 years), including 298 males and 269 females
participated in the study. The average Pcr and cysC levels of
enrolled patients were 1.971.7 mg dl1 (range 0.59–18.6) and
2.171.5 mg l1 (range 0.43–8.3), respectively. The average of
reference GFR (rGFR) measured by 99mTc-DTPA plasma
clearance was 57.9736.4 ml min1 1.73 m2 (range 4.7–167.4).
Causes of CKD and CKD stage classification are shown in Table 1.
Development of cysC-based equations
Two cysC-based GFR-predicting models were constructed
from a random sample of 376 of the 567 patients. In model 1,
inclusion of age and gender only increased the R2 by 0.01,
and did not improve model fit significantly, and so they were
not included in the model (R2¼ 0.85, standard deviation of
residual¼ 0.13, Po0.001 for model fitting):
eGFR1 ¼ 86cysC1:132 ð1Þ
where GFR is in units of ml min1 1.73 m2 and cysC is in
units of mg l1.
Model 2, which included Pcr, age, and gender in addition
to cysC, gave better model fit (R2¼ 0.91, standard deviation
of residual¼ 0.103, Po0.001 for model fitting) compared
with model 1:
eGFR2 ¼176Pcr0:607cysC0:638
Age0:171 ðFemale0:85Þ ð2Þ
where Pcr is in units of mg dl1 and age is in units of years.
The residual plot for model 2 is shown in Figure 1. The
residuals distributed around zero.
The diagnostic performances of the equations
First, the overall diagnostic performances were compared
among eGFR1, eGFR2, eGFR3¼ 175 Pcr1.234 age0.179
(female 0.79) (the modified MDRD equation for Chinese), and
eGFR4
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð86cysC1:132Þ½175Pcr1:234Age0:179
q
ðFemale0:79Þ
(the composite equation constituted from eGFR1 and
eGFR3). All of the eGFRs correlated well with rGFR. Linear
regressions were made using estimated GFR (eGFRs) against
rGFR. eGFR1 and eGFR2 showed less intercepts on y-axis
compared with those of GFR3 and eGFR4, and they also had
higher slope that were significantly closer to the identical line
compared with eGFR3 and eGFR4.
Table 1 | Patients’ characteristics
Causes of CKD
Primary or secondary glomerular disease, N (%) 231 (40.7%)
Hypertension, N (%) 76 (13.4%)
Obstructive kidney disease, N (%) 78 (13.7%)
Renovascular disease, N (%) 69 (12.3%)
Chronic tubulointerstitial disease, N (%) 36 (6.3%)
Diabetic nephropathy, N (%) 27 (4.7%)
Polycystic kidney disease, N (%) 14 (2.6%)
Other causes or causes unknown, N (%) 36 (6.3%)
CKD stages
Stage 1, N (%) 121 (21.3%)
Stage 2, N (%) 125 (22.1%)
Stage 3, N (%) 166 (29.3%)
Stage 4, N (%) 87 (15.4%)
Stage 5, N (%) 68 (11.9%)
BSA, body surface area (m2); CKD, chronic kidney disease.
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Figure 1 | Zero residual scatterplot for model 2. Abbreviations are
as follows: rGFR, reference GFR; eGFR: estimated GFR; model 2: model
constructed from a combination of cystatin C, Pcr, age, and gender,
using the training sample data.
1536 Kidney International (2007) 72, 1535–1542
o r i g i n a l a r t i c l e Y-C Ma et al.: Using cystatin C to improve the performance of creatinine based GFR equations
On the Bland–Altman plot (see Figure 2), the bias of
eGFR1 and eGFR2 were much less than those of eGFR3 and
eGFR4 (495, 608, 875, and 885 for eGFR1, eGFR2, eGFR3, and
eGFR4, respectively). Precisions of eGFR2 and eGFR4 were
significantly higher than those of eGFR1 and eGFR3 (76.6, 56,
68.6, and 56.9 ml min1 1.73 m2 for eGFR1, eGFR2, eGFR3,
and eGFR4, respectively; Table 2).
The medians of difference between eGFR1, eGFR2, eGFR4,
and rGFR were smaller than those of eGFR3 (0.08, 0.51,
1.16, and 0.44 ml min1 1.73 m2 for eGFR1, eGFR2,
eGFR3, and eGFR4, respectively). Also, eGFR2 and eGFR4
showed significantly smaller medians of absolute difference
(8.8, 6.89, 8.51, and 6.53 ml min1 1.73 m2 for eGFR1,
eGFR2, eGFR3, and eGFR4, respectively). The 15 and 30%
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Figure 2 | Bland–Altman plots showing the disagreement between eGFR and rGFR. The solid line represents the regression line of
difference between eGFR and rGFR against average of two methods, dashed lines represent 95% confidence intervals for the regression line,
and dotted lines represent 95% limits of agreement. Abbreviations are as follows: rGFR, reference GFR; eGFR1, GFR estimated by equation based
solely on cysC; eGFR2, GFR estimated by equation based on a combination of cysC and Pcr; eGFR3, GFR estimated by modified MDRD equation;
eGFR4; GFR estimated by the composite equation constituted from modified MDRD equation and the solely cysC-based equation; units for GFR
were all ml min1 1.73 m2. a, b, c and d represent for the results of eGFR1, eGFR2, eGFR3 and eGFR4 respectively.
Table 2 | Overall performances of eGFR compared with rGFR: difference, absolute difference, precision, and accuracy
eGFR1 (ml min
1 1.73 m2) eGFR2 (ml min
1 1.73 m2) eGFR3 (ml min
1 1.73 m2) eGFR4 (ml min
1 1.73 m2)
b (95% CI) 8.17 (2.93, 13.41) 7.64 (3.99, 11.31) 12.81 (8.62, 17.01) 10.12 (6.67, 13.58)
m (95% CI) 0.84 (0.77, 0.92) 0.84 (0.78, 0.89) 0.74 (0.68, 0.80) 0.78 (0.73, 0.84)
R 0.84 0.91 0.86 0.91
r2 0.71 0.83 0.75 0.83
Median of difference
(25%, 75% percentile)
(ml min1 1.73 m2)
0.08 (10.53, 7.88) 0.51 (7.6,6.65) 1.16 (10.83,7.9) 0.44 (9.46, 5. 68)
Median of absolute difference
(25, 75% percentile)
(ml min1 1.73 m2)
8.8 (3.7, 19.4) 6.89* (3.28,13.82) 8.51 (3.99,16.71) 6.53* (3.31, 14.66)
Bias (arbitrary units) 495 608 875 885
Precision (ml min1 1.73 m2) 76.6 56 68.6 56.9
15% accuracy (%) 41.8 50.3 42.9 50.8
30% accuracy (%) 64.4 80.6 76.4 83.2
50% accuracy (%) 89 95.3 91.1 94.2
CI, confidence interval; eGFR1, GFR estimated by equation based solely on cysC; eGFR2, GFR estimated by equation based on a combination of cysC and Pcr; eGFR3, GFR
estimated by modified MDRD equation; eGFR4, GFR estimated by the composite equation constituted from modified MDRD equation and the solely cysC-based equation;
rGFR: reference GFR (ml min1 1.73 m2).
*Po0.05 comparing with eGFR3.
Units for GFR were all ml min1 1.73 m2. Linear regressions of eGFRs against rGFR were made; b represents the intersection with the y-axis, m is the slope with the x-axis, r is
the correlated coefficient, and r2 is the coefficient of determination.
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accuracy of eGFR2 and eGFR4 were somewhat improved
compared with that of eGFR3, but without statistical
significance. The 50% accuracy was comparable among
the four equations. As for eGFR2 and eGFR4, both of them
showed the similar difference, absolute difference, precision
and accuracy, but eGFR2 had less bias compared with eGFR4
(Table 2).
The performances of eGFR1, eGFR2, eGFR3, and eGFR4 in
each stage of CKD were analyzed. In CKD stages 1–2, the
differences between eGFR1, eGFR2, and rGFR were signifi-
cantly less than those of eGFR3 and eGFR4; In CKD stage 3,
eGFR1 showed the smallest difference, and the differences
were comparable for eGFR2, eGFR3, and eGFR4; In CKD
stages 4–5, the eGFR1 showed the largest difference, and the
results were comparable for eGFR2, eGFR3, and eGFR4. The
eGFR2 showed smaller absolute difference in each CKD
stages. Generally, eGFR2 gave the best results among four
equations in each CKD stage (see Figures 3 and 4).
The misclassification of CKD stage for four equations
The stage misclassification of CKD by eGFR1, eGFR2,
eGFR3, and eGFR4 was compared. In CKD stage 1, eGFR1,
eGFR2, and eGFR4 showed smaller percent of CKD stage
misclassification compared with eGFR3 (w
2-test, Po0.05).
The percentage of stage 1 patients who were misdiagnosed as
stage 2 by eGFR3 was 55.2%; this number significantly
decreased to 42.1, 42.1, and 44.7% by eGFR1, eGFR2, and
eGFR4, respectively. In CKD stage 2, there were also smaller
percent of subjects misclassified as in CKD stage 3 by eGFR2
and eGFR4, compared with those of eGFR1 and eGFR3. The
detailed data of misclassification results for patients in stages
3, 4, and 5 are shown in Table 3. Generally speaking, eGFR2
and eGFR4 showed similar performance, that is, lower
misclassification in each stage of CKD.
The final equation
For more precise GFR prediction, all 567 patients were involved;
using the similar methods in model 2, the final equations based
on a combination of cysC and Pcr were remodeled as follows
after smearing adjustment (R2¼ 0.92, standard deviation of
residual¼ 0.096, Po0.001 for model fitting):
eGFR5 ¼169Pcr0:608cysC0:63
Age0:157 ðFemale0:83Þ ð5Þ
The scatter plot of both eGFR2 and eGFR5 (estimated GFR
with Equation (5)) against rGFR was also plotted, and the
results showed that eGFR2 and eGFR5 agree with each other
perfectly (figure not shown).
DISCUSSION
In patients with near-normal kidney function, both the
original MDRD equations in Western CKD patients and
the modified MDRD equations in Chinese CKD patients
underestimated reference GFR.9,10 The clinical applicability
of Pcr-based estimate equations in this patient population
has increasingly been questioned, because the underestimation
might result in an unnecessary investigation and/or referral to
nephrologists, excessive monitoring, and interventions.
In the last decade, dozens of paper have compared the
applicability of cysC with Pcr, in GFR estimation in different
stages of CKD. Perlemoine et al.,23 Christensson et al.,24 and
Mussap et al.25 claimed that plasma cysC is more sensitive in
detecting early or mild diabetic nephropathy patients; similar
conclusions also were obtained in patients with non-diabetic
patients,26,27 in patients with renal transplants,28–30 and in
healthy adults.31 Moreover, after a 4-year follow-up long-
itudinal study, Perkins et al.32 demonstrated 100/cysC could
accurately detect GFR change trends in diabetes patients with
normal or elevated GFR.
A recently published paper by Macdonald et al.33 showed
that cysC level was not independent of lean body mass. Also,
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Figure 3 | Comparison of equations: difference between eGFR
and rGFR. Abbreviations are as follows: CKD1 to CKD5 stood for
chronic kidney disease stage 1 to stage 5, respectively; rGFR,
reference GFR; eGFR1, GFR estimated by equation based solely on
cysC; eGFR2, GFR estimated by equation based on a combination of
cysC and Pcr; eGFR3, GFR estimated by modified MDRD equation;
eGFR4; GFR estimated by the composite equation constituted from
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for GFR were all ml min1 1.73 m2.
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Figure 4 | Comparison of equations: absolute difference between
eGFR and rGFR. Abbreviations are as follows: CKD1 to CKD5 stood
for chronic kidney disease stage 1 to stage 5, respectively; rGFR,
reference GFR; eGFR1, GFR estimated by equation based solely on
cysC; eGFR2, GFR estimated by equation based on a combination of
cysC and Pcr; eGFR3, GFR estimated by modified MDRD equation;
eGFR4; GFR estimated by the composite equation constituted from
modified MDRD equation and the solely cysC-based equation; units
for GFR were all ml min1 1.73 m2.
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Bouvet et al.34 compared equations based on either Pcr, cysC,
or a combination of them, in 100 children and young adults
(age range: 1.4–22.8 years old, mean GFR level:
95 ml min1 1.73 m2); the results showed that the GFR
estimation was significantly improved if the equation
included both Pcr and cysC.
These results support our hypothesis that an equation that
included Pcr, cysC, age, and gender might improve the
performance of GFR-estimating equations based Pcr or cysC
alone. Such a composite equation was also constituted from
modified MDRD equation for Chinese and the solely cysC-
based equation. In fact, we think that the composite equation
is inconvenient to apply in clinical practice. Thus, we
expected that a single equation based on a combination of
cysC and Pcr would give more accurate GFR estimation.
Indeed, our combined equation yielded considerable perfor-
mance improvement compared with those of Pcr- or cysC-
based equations, and slight superiority to the composite
equation in each stage of CKD, particularly in patients with
near-normal kidney function. Statistically speaking, it gave
the best model fit; the R2 was higher than the Pcr-based
modified MDRD equation and the equation based solely on
cysC, and it also showed the smallest standard error of
residual, the smallest difference and absolute difference, and
the highest accuracy.
In this study, stage misclassification was reduced by the
equation based on a combination of cysC and Pcr, especially
in early stages of CKD. The misclassification of CKD stage 1
into stage 2 (eGFRo90 ml min1 1.73 m2) by the combined
Equation (2) was decreased from 55.2 to 42.1% compared
with modified MDRD equation, and CKD stage 2 into stage 3
(eGFRo60 ml min1 1.73 m2) was also decreased from 21.3
to 14.9%. These will help clinicians to estimate GFR and
make diagnosis more correctly, and assure clinicians to make
proper clinical action plan for CKD patients, and avoid
unnecessary clinical interventions. Because the final com-
bined Equation (5) was based on all patients and was
assumed to be more accurate than the combined Equation
(2), we recommended that the combined Equation (5) be
used in clinical practice.
In CKD stages 5, 4, and 3, the performance of the equation
based on a combination of cysC and Pcr, was only slightly
superior to the modified MDRD equation. This may be due
to the fact that the non-renal clearance of cysC in humans is
substantially higher in humans with moderately/severely
reduced kidney function.13 Thus, plasma cysC might
be unsuitable as a GFR marker in advanced kidney failure.
Since it is currently more expensive to measure cysC than
Pcr (cysC is about US $8.5, while Pcr is approximately US
$0.75), and the modified MDRD equation can provide
Table 3 | Percentages of CKD stage misclassification by Pcr- and cysC-based equations in CKD stages 1–5
CKD staged by rGFR
CKD stage 1 CKD stage 2 CKD stage 3 CKD stage 4 CKD stage 5
Classification based on eGFR1
CKD stage 1 57.9* 19.1 3.5 0 0
CKD stage 2 42.1 59.6 20.7 0 0
CKD stage 3 0 21.3 50 24.1 0
CKD stage 4 0 0 25.8 62.1 47.4
CKD stage 5 0 0 0 13.8 52.6
Classification based on eGFR2
CKD stage 1 57.9* 10.6 0 0 0
CKD stage 2 42.1 74.5 17.1 0 0
CKD stage 3 0 14.9 69.1 20.7 0
CKD stage 4 0 0 13.8 62.1 26.3
CKD stage 5 0 0 0 17.2 73.6*
Classification based on eGFR3
CKD stage 1 44.8 10.6 1.8 0 0
CKD stage 2 55.2 68.1 13.8 0 0
CKD stage 3 0 21.3 81 24.1 0
CKD stage 4 0 0 3.4 62.1 36.8
CKD stage 5 0 0 0 13.8 63.2
Classification based on eGFR4
CKD stage 1 55.3* 10.6 0 0 0
CKD stage 2 44.7 74.5 15.6 0 0
CKD stage 3 0 14.9 74.1 20.7 0
CKD stage 4 0 0 10.3 68.9 36.8
CKD stage 5 0 0 0 10.4 63.2
CKD, chronic kidney disease; CKD1 to CKD5 stood for chronic kidney disease stage 1 to stage 5, respectively; cysC, cystatin C; eGFR1, GFR estimated by equation based solely
on cysC; eGFR2, GFR estimated by equation based on a combination of cysC and Pcr; eGFR3, GFR estimated by modified MDRD equation; eGFR4; GFR estimated by the
composite equation constituted from modified MDRD equation and the solely cysC-based equation; Pcr, plasma creatinine; rGFR, reference GFR ml min1 1.73 m2; units for
GFR were all ml min1 1.73 m2.
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acceptable accuracy in CKD stage 5, 4, and 3 we
recommended the modified MDRD equation in advanced
kidney failure.
There are also some limitations of this study. First, rGFR
measurement by 99mTc-DTPA plasma clearance method was
still used in this study. This method can provide enough
accuracy in GFR measurement, and was recommended by the
Nephrourology Committee of Society of Nuclear Medi-
cine.35,36 It is, however, different from the renal clearance of
125I-iothalamate that used in the MDRD study. Studies
have shown that dual blood sampling overestimates GFR at
lower levels (by an average of 0.5 ml min1 when GFR¼
10 ml min1) and underestimates GFR at higher levels (by
an average of 20 ml min1 when GFR¼ 100 ml min1),37
whereas the renal clearance of 125I-iothalamate overestimated
renal clearance of inulin by 3–5 ml min1 at low levels of GFR
and by 15–25 ml min1 in healthy subjects.38–41
Second, there are several methods to measure plasma cysC
in clinical laboratories. The use of different assay systems and
calibrators had been reported to probably contribute to the
differences in the reference values of plasma cysC,42 which
could cause problems when cysC-based equation for GFR
was used. In order to achieve maximal diagnostic perfor-
mance, the difference assay systems would require slightly
different prediction equations. In this study, we used an
immunonephelometry assay method to measurement plasma
cysC that had higher accuracy than other method in cysC
measurement.43
Third, the equation is based on data from Chinese CKD
patients, and so it is not clear if it is applicable to other racial
population. Subjects with certain clinical condition were
excluded from the study, such as patients with edema or on
steroid. The developed equation will not be suitable for this
group of patients.
In summary, we added cysC into Pcr-based, GFR-
estimating equation, which achieved a better agreement with
reference GFR, compared with modified MDRD equation,
especially in early detection of CKD. We also suggest that a
better understanding of factors that affect cysC and Pcr levels
independent of GFR (such as in patients with edema,
skeletal muscle atrophy, malnutrition, amputation can
cause the levels of Pcr to decrease, and hyperthyroidism,
malignant tumor and acute inflammatory conditions may
lead to the levels of cysC to increase) could potentially
improve the proper use of GFR-estimating equation in
clinical practice.
MATERIALS AND METHODS
Subjects and design
This was part of the protocol of Chinese eGFR cooperate study
program.9 Nine renal institutes of university hospital located in nine
different geographic regions of China participated in this study from
June 2004 to September 2005. The same patient inclusion and
exclusion criteria were used in all of the participating renal institutes
as described previously.9 Briefly, patients with CKD aged more than
18 years were eligible for inclusion. CKD was diagnosed and
classified according to Kidney Disease Outcome Quality Initiatives
clinical practice guideline.7 Patients with acute kidney function
deterioration, edema, skeletal muscle atrophy, pleural effusion or
ascites, malnutrition, amputation, heart failure, ketoacidosis,
hypothyroidism or hyperthyroidism, malignant tumor, and acute
inflammatory conditions were excluded. Patients who were
currently taking high-dose steroids, cimetidine, trimethoprim, or
who were on any kind of renal replacement therapy, were also
excluded. From the total 684 patients in the previous study, 573
cases with available cysC results were included in this study.
The nine participating renal institutes used the same data
collecting method and the same data collection form. The collected
data included sex, age, body height, body weight, blood pressure,
and GFR. Fasting plasma of the selected patients were taken and
stored at 301C before analysis, and all of the blood samples were
transferred a the single laboratory (Department of Laboratory,
Peking University First Hospital) in freezed condition for analysis of
cysC and Pcr.
This study was approved by the local Ethics Committee and
written informed consent was obtained from all patients enrolled
into the study.
Methods
GFR measurement. rGFR was measured using 99mTc-DTPA
plasma clearance method as described previously.9 Among the nine
participating renal institutes, efforts had been made to make the
inter-institute variance as small as possible, including staff training
and 99mTc-DTPA drug selection (radiochemical purity greater than
95%, percentage of 99mTc-DTPA bound to plasma protein less than
5%). The identical operational procedures were followed by all the
nine participating centers, including patients’ preparation, intrave-
nous injection, plasma sampling time point and procedure, and
radioactivity measurement.10
rGFR was calculated using dual plasma sampling method,35,36
standardized by body surface area,44 and resulted in the rGFR
equation:
rGFR ðml min1=1:73m2Þ ¼fDln ðP1=P2Þ=ðT2  T1Þg exp f½ðT1 ln P2Þ
 ðT2 ln P1Þ=ðT2  T1Þg0:931:73=BSA:
where D is dosage of drug injected, T1 is time of first blood
sampling (B2 h), P1 is plasma activity at T1, T2 is time of second
blood sampling (B4 h), and P2 is plasma activity at T2. The units of
measurement were counts per minute, per milliliter for D, P1, and
P2, and minutes for T1 and T2. BSA is the abbreviated form of body
surface area.
Measurement of Pcr and plasma cysC. Pcr and plasma cysC
measurement was performed in a single laboratory (Department of
Laboratory, Peking University First Hospital); Pcr was measured by
the Jaffe’s kinetic method, described elsewhere,10 on a Hitachi 7600
autoanalyzer (Hitachi Company, Chiyoda-ku, Tokyo, Japan);
normal reference range was 0.72 to 1.48 mg dl1 (64–131mmol l1);
plasma cysC was measured by automated particle-enhanced
immunonephelometry method using a BN 100 nephelometer
(Dada Behring, Marburg, Germany), the coefficients of variation
were 2.1% at cysC concentration of 1.0 mg l1 and 1.8% at cysC
concentration of 4.0 mg l1 during the study period; normal
reference range was 0.50 to 1.17 mg l1.
Estimation of GFR with modified abbreviated MDRD equation
for Chinese, and a composite equation constituted from modified
MDRD equation and the solely cysC-based equation. Hitachi Pcr
was put into modified abbreviated MDRD equation to estimate GFR
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(eGFR3) (R
2¼ 0.86, standard deviation of residual¼ 0.136,
Po0.001 for model fitting)9:
eGFR3 ¼ 175Pcr1:234age0:179 ðfemale0:79Þ ð3Þ
Estimate GFR using the composite equation was as follow:
eGFR4
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð87cysC1:132Þ½175Pcr1:234Age0:179ðFemale0:79Þ
q
ð4Þ
New equation development methods and statistical analy-
sis. First, from the selected 573 patients, six individuals were
excluded (they were excluded because the values of cysC, Pcr, or
rGFR were considered measurement error). The remaining 567 cases
were used for further analysis. From these cases, 376 cases were
randomly selected to be included in the regression model, the
remaining 191 cases were used as validation set. We used an
approach similar to that used to develop the MDRD equations, that
is, the logarithmic-transformed rGFR was regressed on logarithmic-
transformed plasma cysC, age, and sex in model 1, and logarithmic-
transformed Pcr was added to model 1 to expand the model to
model 2. Multiple stepwise regression was used; P-value less than
0.05 was used as inclusion criteria and a P-value greater than 0.10
was used as exclusion criteria. In the concern that retransforming
back to the usual scale might induce bias, the predicted eGFR was
adjusted using smearing method.45 The smearing coefficients for
these two models were calculated to be 1.04 and 1.02, respectively.
The model fit (R2) and standard deviation of residual among
different predictive models were compared.
Second, eGFRs estimated using the equation based solely on
cysC, the equation based on a combination of cysC and Pcr, the
modified MDRD equation, and the composite equation were
compared with rGFR using Bland–Altman analysis in the validation
set. The difference between eGFR and rGFR was defined as eGFR
minus rGFR, the absolute difference between eGFR and rGFR was
defined as the absolute value of difference. The difference between
eGFR and rGFR was regressed against the average of the two
methods. The bias for eGFR was expressed as the area between the
regression line and a common distance along the zero-difference
line. Ninety-five percent limits of agreement were constructed
around this regression line. The precision was expressed as the width
between the 95% limits of agreement. Accuracy was measured as the
percentage of estimated GFR not deviating more than 15, 30, and
50% from the rGFR. The accuracy of the estimating equation in
different stages of CKD was compared with w2-test.
Quantitative variables were described as mean7standard devia-
tion or median. Because of skewed distribution, Spearman
correlation and linear regression were used to describe the relation-
ship between eGFRs and rGFR. The Wilcoxon signed ranks test was
used to compare the difference and absolute difference for a certain
stage of CKD. The results were considered to be significant if the
P-value was less than 0.05. Microsoft Office Excel 2003 (Microsoft
Corporation) and Medcalc for Windows, version 8.0 (Medcalc
software, Mariekerke, Belgium) were used in statistical analysis.
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